Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05983991
NA

Study for Characterisation of Predictive Parameters of Clonal Evolution in Subjects With GATA2 Germline Mutation

Sponsor: Institut Claudius Regaud

View on ClinicalTrials.gov

Summary

This trial is a translational, open-label, multi-site, retrospective and prospective cohort study of 250 patients aiming to characterize predictive parameters of clonal evolution in a population of subjects carrying the germline GATA2 mutation. This study will be conducted on a population of subjects either with previous germline GATA2 mutation identified or newly identified for germline GATA2 mutation in the context of routine care. Prospective cohort: 150 subjects will be included in this interventional prospective cohort study: * Alive subjects previously identified with a germline GATA2 mutation through the already existing "Neutropenia database"; * Subject identified in the investigating centers in the context of a newly identified germline GATA2 mutation. For each included patient, biological samples (blood and bone marrow samples) will be collected at baseline visit and then during 5 years, according to the samples taken in the standard practice. No additional sampling will be performed for the study. Retrospective cohort: Subjects (100 cases in total) previously identified with germline GATA2 mutation through the already existing "Neutropenia database" and with the following features may enter the retrospective cohort: * Deceased patients, * Lost to follow-up patients. Clinical follow-up data will be obtained from this database and/or patient's medical report. For each retrospective case, archived blood and bone marrow samples (collected in a sanitary setting) will be sent to sponsor's centralized unit for analysis.

Official title: GATA-2 Project: Retrospective and Prospective Exploratory Study for Characterisation of Predictive Parameters of Clonal Evolution in Subjects With GATA2 Germline Mutation

Key Details

Gender

All

Age Range

Any - Any

Study Type

INTERVENTIONAL

Enrollment

150

Start Date

2023-12-07

Completion Date

2033-12

Last Updated

2025-12-26

Healthy Volunteers

Yes

Interventions

OTHER

Biological samples (blood and bone marrow samples).

For each included patient, biological samples (blood and bone marrow samples) will be collected at baseline visit and then during 5 years, according to the samples taken in the standard practice. No additional sampling will be performed for the study.

Locations (23)

CHU Angers

Angers, France

CHU Bordeaux

Bordeaux, France

CHU Estaing

Clermont-Ferrand, France

CHU Dijon

Dijon, France

CHU de Grenoble

Grenoble, France

CHRU - Lille

Lille, France

IHOP Lyon

Lyon, France

CHU La Timone

Marseille, France

CHU Arnaud de Villeneuve

Montpellier, France

CHU Nantes

Nantes, France

CHU de Nice

Nice, France

Hôpital Armand Trousseau

Paris, France

Hôpital Robert Debré

Paris, France

Hôpital Saint-Louis

Paris, France

CHU Rennes

Rennes, France

CHU Hôpitaux de Rouen - Charles Nicolle

Rouen, France

CHU Saint-Etienne

Saint-Priest-en-Jarez, France

Hôpital Necker

Sèvres, France

CHU Strasbourg

Strasbourg, France

CHU Purpan - Hôpital des Enfants

Toulouse, France

Institut Universitaire Du Cancer Toulouse - Oncopole (Iuct-O)

Toulouse, France

CHRU de Tours

Tours, France

CHRU Nancy Hôpital d'enfants

Vandœuvre-lès-Nancy, France